NCT00668512View on ClinicalTrials.gov

Intratumoral Injection Of Alpha-Gal Glycosphingolipids

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

Antimelanoma injection of GSL alpha-Gal

Single arm, phase 1 trial of escalating doses of GSL alpha-Gal (0.1mg, 1mg, 10mg)injected into a melanoma metastasis at day 0 and then again 4 weeks later.

Trial Locations (1)

53792

Universiity of Wisconsin, Madison

All Listed Sponsors
lead

University of Massachusetts, Worcester

OTHER

NCT00668512 - Intratumoral Injection Of Alpha-Gal Glycosphingolipids | Biotech Hunter | Biotech Hunter